AIM： To focus on the role of CD40 and CD40L in their pathogenesis. METHODS： We analyzed by immunohistochemistry the CD40 and CD40L expression in the pouch mucosa of 28 patients who had undergone RPC for UC, in the t...AIM： To focus on the role of CD40 and CD40L in their pathogenesis. METHODS： We analyzed by immunohistochemistry the CD40 and CD40L expression in the pouch mucosa of 28 patients who had undergone RPC for UC, in the terminal ileum of 6 patients with UC and 11 healthy subjects. We also examined by flow cytometry the expression of CEH0 by B lymphoo/tes and monocytes in the peripheral blood of 20 pouch patients, 15 UC patients and 11 healthy controls. RESULTS： Ileal pouch mucosa leukocytes presented a significantly higher expression of CD40 and CD40L as compared to controls. This alteration correlated with pouchitis, but was also present in the healthy pouch and in the terminal ileum of UC patients. CD40 expression of peripheral B lymphocytes was significantly higher in patients with UC and pouch, respect to controls. Increased CD40 levels in blood B cells of pouch patients correlated with the presence of spondyloarthropathy, but not with pouchitis, or inflammatory indices. CONCLUSION： High CD40 expression in the ileal pouch mucosa could be implied in the pathogenesis of pouchitis following proctocolectomy for UC, whereas its increased levels on peripheral blood B lymphocytes are associated with the presence of extraintestinal manifestations.展开更多
The ultimate goal of antitumor vaccines is to develop memory CD8＋ cytotoxic T lymphocytes （CTLs）, which are critical mediators of antitumor immunity. We previously demonstrated that the ovalbumin （OVA）-specific ...The ultimate goal of antitumor vaccines is to develop memory CD8＋ cytotoxic T lymphocytes （CTLs）, which are critical mediators of antitumor immunity. We previously demonstrated that the ovalbumin （OVA）-specific CD4＋ T cell-based （OVA-TExo） vaccine generated using OVA-pulsed dendritic cell （DCovA）-released exosomes （EXOovA） stimulate CTL responses via IL-2 and costimulatory CD80 signaling. To assess the potential involvement of other costimulatory pathways and to define the key constituent of costimulation for memory CTL development, we first immunized wild-type （WT） C57BIJ6 and gene-knockout mice with WT CD4~ OVA-TExo cells or OVA-TExo cells with various molecular deficiencies. We then assessed OVA-specific primary and recall CTL responses using PE-H-2Kb/ 0VA257_264 tetramer and FITC-anti-CD8 antibody staining by flow cytometry. We also examined antitumor immunity against the OVA-expressing B16 melanoma cell line BL6-1OovA. We demonstrated that CD4＋ OVA-TExo cells stimulated more efficient CTL responses compared to DCovA. By assessing primary and recall CTL responses in mice immunized with OVA-TExo or with OVA-TExo lacking the costimulatory molecules CD4OL, 4-1BBL or OX4OL, we demonstrated that these costimulatory signals are dispensable for CTL priming by OVA-TExo. Interestingly, CD4OL, but not 4-1BBL or OX4OL, plays a crucial role in the development of functional memory CTLs against BL6-1OovA tumors. Overall, this work suggests that a novel CD4＋ T cell-based vaccine that is capable of stimulating long-term functional CTL memory via CD40L signaling may represent a novel, efficient approach to antitumor vaccination.展开更多
文摘AIM： To focus on the role of CD40 and CD40L in their pathogenesis. METHODS： We analyzed by immunohistochemistry the CD40 and CD40L expression in the pouch mucosa of 28 patients who had undergone RPC for UC, in the terminal ileum of 6 patients with UC and 11 healthy subjects. We also examined by flow cytometry the expression of CEH0 by B lymphoo/tes and monocytes in the peripheral blood of 20 pouch patients, 15 UC patients and 11 healthy controls. RESULTS： Ileal pouch mucosa leukocytes presented a significantly higher expression of CD40 and CD40L as compared to controls. This alteration correlated with pouchitis, but was also present in the healthy pouch and in the terminal ileum of UC patients. CD40 expression of peripheral B lymphocytes was significantly higher in patients with UC and pouch, respect to controls. Increased CD40 levels in blood B cells of pouch patients correlated with the presence of spondyloarthropathy, but not with pouchitis, or inflammatory indices. CONCLUSION： High CD40 expression in the ileal pouch mucosa could be implied in the pathogenesis of pouchitis following proctocolectomy for UC, whereas its increased levels on peripheral blood B lymphocytes are associated with the presence of extraintestinal manifestations.
文摘The ultimate goal of antitumor vaccines is to develop memory CD8＋ cytotoxic T lymphocytes （CTLs）, which are critical mediators of antitumor immunity. We previously demonstrated that the ovalbumin （OVA）-specific CD4＋ T cell-based （OVA-TExo） vaccine generated using OVA-pulsed dendritic cell （DCovA）-released exosomes （EXOovA） stimulate CTL responses via IL-2 and costimulatory CD80 signaling. To assess the potential involvement of other costimulatory pathways and to define the key constituent of costimulation for memory CTL development, we first immunized wild-type （WT） C57BIJ6 and gene-knockout mice with WT CD4~ OVA-TExo cells or OVA-TExo cells with various molecular deficiencies. We then assessed OVA-specific primary and recall CTL responses using PE-H-2Kb/ 0VA257_264 tetramer and FITC-anti-CD8 antibody staining by flow cytometry. We also examined antitumor immunity against the OVA-expressing B16 melanoma cell line BL6-1OovA. We demonstrated that CD4＋ OVA-TExo cells stimulated more efficient CTL responses compared to DCovA. By assessing primary and recall CTL responses in mice immunized with OVA-TExo or with OVA-TExo lacking the costimulatory molecules CD4OL, 4-1BBL or OX4OL, we demonstrated that these costimulatory signals are dispensable for CTL priming by OVA-TExo. Interestingly, CD4OL, but not 4-1BBL or OX4OL, plays a crucial role in the development of functional memory CTLs against BL6-1OovA tumors. Overall, this work suggests that a novel CD4＋ T cell-based vaccine that is capable of stimulating long-term functional CTL memory via CD40L signaling may represent a novel, efficient approach to antitumor vaccination.
